Business
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including men
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"list","items":[{"val":[{"type":"text","content":"Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI","length":293,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":636,"olType":false},{"type":"text","content":"NEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including menin and FLT3 inhibitors and the hypomethylating agent (HMA) azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations. Additionally, in animal models, Actimab-A significantly enhanced tumor growth inhibition, prolonged the duration of response and survival when combined with the menin inhibitor revumenib (Syndax Pharmaceuticals, Inc.), and potentiated AML cell killing in combination with the FLT3 inhibitor gilteritinib (Astellas Pharma US, Inc.) and HMA azacitidine.","length":1085,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"re...